

# SYNTHESIS, CHARACTERISATION AND ANTIMICROBIAL STUDIES OF METAL(II) COMPLEXES OF TRIMETHOPRIM AND 2,2' BIPYRIDINE HETEROCYCLE

\*<sup>1</sup>Tunmise T. Eugene-Osoikhia, <sup>1</sup>Sodeeq A. Ojeyemi, <sup>1</sup>Raymond A. Akong,
 <sup>2</sup>Temidayo Oyetunde, <sup>3</sup>Emmanuel U. Onche, <sup>4</sup>Funmilola Ayeni
 <sup>1</sup>Department of Chemistry, University of Ibadan, Ibadan, Nigeria

<sup>2</sup> Department of Chemical Sciences, Redeemer's University, Ede, Nigeria

<sup>3</sup>School of Chemistry, University of Manchester, Manchester, United Kingdom

<sup>4</sup>Department of Pharmaceutical Microbiology, University of Ibadan, Ibadan, Nigeria

\* Corresponding Author: kemitunmise@yahoo.co.uk

# ABSTRACT

Mixed-ligand complexes of trimethoprim (TMP) with 2,2'-bipyridine (bipy) with the formular [M(TMP)(bipy)X].nH<sub>2</sub>O, where M = Mn(II), Co(II), Ni(II), Cu(II), Fe(II), Zn(II) and X= Cl/SO<sub>4</sub>, were synthesized and characterized by percentage metal, infrared, electronic spectroscopies, room temperature magnetic moments, melting points, conductance measurements and elemental analysis. From the infrared spectral data, TMP behaves as a bidentate ligand bonding to the metals via the N atom of the pyrimidine amino group (3412-3300 cm<sup>-1</sup>) and nitrogen atom of the azomethine moiety (1666-1639 cm<sup>-1</sup>) while the bipy coordinated through the diimine nitrogen atoms (1593-1404 cm<sup>-1</sup>). The room temperature magnetic moment and electronic spectra indicated that the metal(II) complexes were monomeric and octahedral. The molar conductance of the synthesised complexes in the range 24-40  $\Omega^{-1}$  cm<sup>2</sup> mol<sup>-1</sup> confirmed their non-electrolytic and covalent nature. The antimicrobial studies showed that the complexes were inactive towards the tested fungus but possessed good antibacterial activities. The observed trend for the antibacterial activities demonstrated by the mixed metal complexes was in the order Mn >Zn > Cu > Fe > Co ~ Ni thus making [Mn(TMP)(bipy)Cl<sub>2</sub>].2H<sub>2</sub>O the most biologically active among them. It was also observed that antibacterial activities exhibited varied directly with concentration as the highest activities were observed at the highest concentration of 40 mg/mL.

# **Keywords:** Antimicrobial, 2,2'-bipyridine, Complexes, Heterocycle, Trimethoprim, Mixed-ligands.

#### **INTRODUCTION**

Development of antimicrobial drugs was one of the great medical accomplishments of the twentieth century [1]. The present resistance against antimicrobial agents has become public health problem worldwide [2–8]. In the search for novel drugs against drug resistant diseases, the use of metal complexes has received tremendous awareness and had resulted in a variety of exciting and important drugs such as *cis*-platin [9-17]. Trimethoprim (TMP) (Fig. 1), chemically known as 5-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine is a broad-spectrum antimicrobial agent used in prophylaxis treatment and urinary tract infections [18]. It is a structural analoque of pteridine fraction of dihydrofolic acid which competitively inhibits dihydrofolatereductase [19-20]. As a pyrimidine inhibitor of bacterial dihydrofolatereductase, it binds tightly to the bacterial enzyme, blocking the production of tetrahydrofolic acid from dihydrofolic acid [21].



Figure 1: Structure of trimethoprim

Most gram-negative and gram-positive microorganisms are sensitive to trimethoprim, but resistance can develop when the drug is used as a single therapy [22]. Thus, it is normally used as combination therapy with sulfamethoxazole in 1 to 5 ratios [23] to give sequential and synergistic inhibition of bacterial folate metabolism [24]. As a fixed combination formulation it is applied in the treatment of respiratory tract infections such as bronchitis [25], *Pneumocystis carinii* pneumonia with AIDS [26-27], severe urinary tract infections [28] and enteric infections [29]. The combination of trimethoprim-sulfamethoxazole has been outstandingly successful [23]. However, it has been suggested that the clinical conquest of this combination is due mainly to the efficacy of TMP [23]. Therefore, the recent decline in the clinical importance of TMP-SMZ combination as a first line therapy for several infections due to the emergence of resistance disease pathogens and serious side effects of sulfamethoxazole (sulfonamides) [20, 30] requires modification of the combination by the search for an alternative to sulfamethoxazole.

Heterocycles and their derivatives have been reported to have remarkable broad spectrum of biological activities [31-32]. Nitrogen heterocycles are one of the most important classes of ligands in coordination chemistry [33-36]. Among the nitrogen heterocycles, 2,2'-bipyridine (bipy) (Fig. 2) have been widely used as a chelating donor site due to its robust redox stability and relative ease of functionalization [37]. It is an attractive core structure of a large class of chelating compounds that are able to form stable complexes with metal ions [38-39]. Numerous classes of biologically active natural products share this core structure such as caerulomycins [40-42], collismycins [43], orellanine [44], camptothecin [45] and streptonigrinoids [46].

Mixed-ligand complexes involving heterocyclic bases such as pyridine, 2,2'-bipyridine, o-phenanthroline, have been reported due to their bioinorganic applications, thermal stability [47-49], antineoplasticity, cytotoxicity, antitumor effect, genotoxicity, and bactericidal effect [50-51]. Few reports are available on the mixed metal complexes of trimethoprim [52]. Osowole *et al* reported mixed drug metal(II) complexes of trimethoprim and sulfamethoxazole [53], isoniazid and trimethoprim was synthesised by Bamgbose *et al* [54], but no report was available on mixed ligand of 2,2'-bipyridine and trimethoprim. Here, we report the mixed-ligand complexes of trimethoprim and 2,2'-bipyridine and their antimicrobial activities.



Figure 2: Structure of 2,2'-Bipyridine

## EXPERIMENTAL

#### **Materials and Reagents**

All reagents and solvents were of analytical grade and used without further purification. Trimethoprim was gift from Bond Pharmaceutical company Plc, Oyo, Nigeria while 2,2'-bipyridine, cobalt(II) chloride hexahydrate, copper(II) chloride dihydrate, manganese(II) chloride tetrahydrate, iron(II) sulphate heptahydrate, nickel(II) chloride hexahydrate and zinc(II) sulphate heptahydrate, were obtained from Aldrich chemicals.

#### **Physical measurements**

The electronic spectra of the complexes in DMSO were recorded on a Perkin-Elmer Lambda 25 Spectrophotometer and infrared spectra were recorded as KBr disc on a Perkin-Elmer BX II FT-IR spectrometer 4000–370 cm<sup>-1</sup>. The room temperature magnetic susceptibilities at 303K were measured on Sherwood Susceptibility Balance MSB Mark 1 and diamagnetic corrections were calculated using Pascal's constant, melting points were determined with Stuart SMP10 melting point apparatus and conductivity measurement was obtained using a Labtech Digital conductivity mechanical device in 1 x  $10^{-3}$  M solutions of nitromethane. CHN elemental analysis was carried out at University of Manchester using Flash 2000 elemental Analyser.

# Synthesis of Metal Complexes of [M(TMP)(bipy)X].nH O, where X= Cl/SO4]

A previously reported procedure by Osowole *et al* was employed with slight modification in the synthesis of the metal(II) complexes of trimethoprim and 2,2'-bipyridine [53]. Trimethoprim 0.5 g (1.72 mmole) and 2,2'-bipyridine 0.2690 g (1.72 mmole) were dissolved in 30 ml of methanol. To the resulting homogenous solution, equimolar amount (1.72 mmole) of the respective metal(II) salt in 1:1:1 stochiometric was added dry in bits with continuous stirring at 60 °C. The resulting solution was then refluxed for 6 hours to give the product. This was then kept and left undisturbed for about 4 - 6 days to aid the complex precipitation. The resulting complexes were dried over silica gel. The preparation is given by equations (I) and (II) respectively:

## **Equation of the reaction**

$$\begin{split} & MCl_2.xH_2O + TMP + bipy \longrightarrow [M(TMP)(bipy)Cl_2].nH_2O + yH_2O \dots (I) \\ & (where M = Ni, x= 6, n= 0, y= 6; M= Mn, x= 4, n=2, y=2; M= Cu, x=2, n=2, y=0; M= Co, x=6, n=0, y=6) \\ & MSO_4.xH_2O + TMP + bipy \longrightarrow [M(TMP)(bipy)SO_4].nH_2O + yH_2O \dots (II) \\ & (where M = Fe, x=7, n=3, y=4; M= Zn, x=7, n=3, y=4) \end{split}$$

## **Antimicrobial Studies**

Antimicrobial screening of the free ligands and the synthesized complexes were tested in vitro using Agar diffusion method [54-56]. The prepared culture plates were innoculated with different identified clinical strains of gram positive, gram negative bacteria and a fungus: *Staphylococcus aureus, Enterotoxigenic E. coli, Enteropathogenic E. coli, Klebsiella pneumonia,* 

http://www.unn.edu.ng/nigerian-research-journal-of-chemical-sciences/

*Leclercia adecarboxylata, Morganella morganii, Salmonella typhi* and a fungus *Candida albicans.* The bacteria were cultured using the pour-plate method. From the diluted organisms  $(10^{-2})$ , 0.2 ml was injected into the prepared sterile nutrient agar which was at 45 °C, then aseptically poured into sterile petri dishes, which were allowed to solidify for about 45-60 minutes. Wells were made on the agar surface with 6 mm sterile cork borer. The prepared different graded concentrations of the complexes and the ligand were poured into the well using sterile syringes. The plates were incubated at 37 °C  $\pm$  2 °C for 24 hours. The plates were observed for the zone clearance around the wells. The zone of inhibition was calculated by measuring the diameter of the inhibition zone around the well (in mm) including the well diameter. The experiments were conducted in triplicates with gentamycin used as positive control.

Sterile Sabourad Dextrose Agar was prepared for fungus culture. The prepared agar was poured into sterile plates in triplicates allowed to set properly. The organisms (0.2ml) (*Candida albicans*) were spread to cover the surface of the agar. Wells were also made using sterile cork borer of 6 mm in diameter this was followed by the introduction of the prepared concentrations of the ligands and their complexes. The plates were left on the bench for 2 hours to allow pre diffusion and then incubated at  $25 \pm 2$  °C for 48 hours. Ketoconazole was used as reference drug.

#### **RESULTS AND DISCUSSION**

The complexes Figures 3 and 4 exhibit variety of colours with their percentage yields ranging from 36 - 98% as shown in Table 1. The resultant complexes are soluble mainly in DMF and DMSO and are non-electrolytes. The low values of the molar conductivity of the compounds in the range 24-38  $\Omega^{-1}$ cm<sup>2</sup>mol<sup>-1</sup> indicate that they are non-electrolyte in solution [57]. The analytical data, melting point/decomposition temperatures and room temperature magnetic moments of the complexes are presented in Table 1

Table 1: Physical and analytical data for the complexes

Complexes	Empirical Formula	Formular mass	M.pt (°C)	μ <sub>eff</sub> ( <b>B</b> M)	AM	% Yield	Element	al Analysis	s(Found)	
		(g/mol)		( <b>D</b> .1 <b>v</b> 1)	$\Omega^{-1}$ cm <sup>2</sup> mol <sup>-1</sup>		С	Н	N	М
Trimethoprim (TMP)		290.32	228- 239	-	-	-				
2,2'-bipyridine (bipy)		156.19	72- 75	-	-	-				
[Co(TMP)(bipy)Cl <sub>2</sub> ]	$[C_{0}C_{24}H_{26}N_{6}O_{3}Cl_{2}]$	575.93	196	3.3	40	42.49	50.01 (51.03)	4.55 (5.00)	14.58 (14.62)	10.22 (10.39)
[Cu(TMP)(bipy)Cl <sub>2</sub> ].2H <sub>2</sub> O	$[CuC_{24}H_{26}N_6O_3Cl_2].2H_2O$	616.55	230	1.8	38	79.77	46.71 (46.68)	4.25 (4.29)	13.62 (13.59)	10.94 (10.64)
[Fe(TMP)(bipy)SO <sub>4</sub> ].3H <sub>2</sub> O	$[FeC_{24}H_{26}N_6O_3SO_4].3H_2O$	651.85	245*	3.1	24	48.83	44.18 (44.25)	3.99 (3.87)	12.89 (12.93)	9.33 (9.37)
[Mn(TMP)(bipy)Cl <sub>2</sub> ].2H <sub>2</sub> O	[MnC <sub>24</sub> H <sub>26</sub> N <sub>6</sub> O <sub>3</sub> Cl <sub>2</sub> ].2H <sub>2</sub> O	607.93	250*	2	35	88.72	47.37 (48.01)	4.27 (4.30)	13.82 (13.84)	8.77 (8.73)
[Ni(TMP)(bipy)Cl <sub>2</sub> ]	$[NiC_{24}H_{26}N_6O_3Cl_2]$	575.69	242*	2.2	38	36.07	50.02 (50.00)	4.51 (4.86)	14.59 (14.62)	10.19 (10.21)
[Zn(TMP)(bipy)SO <sub>4</sub> ].2H <sub>2</sub> O	$[FeC_{24}H_{26}N_6O_3SO_4].3H_2O$	643.41	253*	D	24	98.02	44.76 (44.63)	4.04 (4.07)	13.05 (13.09)	10.76 (10.74)

 $D = diamagnetic, *= decomposition temperature, Molar conductance (^M) = \Omega^{-1} cm^2 mol^{-1}$ , Exp =experimental,  $\mu eff = effective magnetic moments$ , M. pt = melting point

#### **Infrared Spectra Studies of Synthesized Complexes**

The relevant infrared data are presented in Table 2. IR spectra of trimethoprim, 2,2' bipyridine and their metal complexes were studied and assigned based on careful assessment of their spectra. The characteristics asymmetric  $v(NH)_{asy}$  and symmetric  $v(NH)_{sym}$  stretching vibrations of pyrimidine amino group (NH<sub>2</sub>) of free TMP at 3466 and 3313 cm<sup>-1</sup> [58] were shifted in all the complexes in the region 3412- 3300 cm<sup>-1</sup> showing the bonding of the amino group's nitrogen to the metal(II) ions without deprotonation [59]. The azomethine v(C=N), band at 1641 cm<sup>-1</sup>in TMP shifted in the range 1666 - 1639 cm<sup>-1</sup> in the metal complexes confirming the participation of the azomethine nitrogen atom in bonding to the metal(II) ions [60-61].

The binding of the bipy was indicated by the shift of the diimine ((C=C), (C=N)) ring stretching vibration to higher frequencies in the spectra of the complexes [62-65]. Appearance of new bands in the range (626-510) cm<sup>-1</sup> and (508-474) cm-1 were attributed to the stretching frequencies of (M-N) and (M-O) bonds respectively. Again, new bands in the range 381-370 cm<sup>-1</sup> were assigned to M–Cl stretching vibrations in the complexes. In all the complexes except [Co(TMP)(bipy)Cl<sub>2</sub>] and [Ni(TMP)(bipy)Cl<sub>2</sub>] the existence of lattice/coordinated water molecules were shown by the appearance of broad bands in the region 3480–3550 cm<sup>-1</sup> [66].

Table 2: Relevant IR data of trimeth	noprim, 2,2'-b	ipyridine and th	eir metal complexe	es in cm <sup>-1</sup>			
Compounds	V(OH)/H2O	V (NH2) (amino)	V (C=N) ( <b>pyrimidine</b> )	V (C=C/C=N) (diiminegrp)	V(M-N)	V(M-0)	V(M-CI)
Trimethoprim (TMP)	_	3466(asy) 3313(sym)	1641	_	_	_	_
2,2'-bipyridine (bipy)	_	_	_	1566,1557, 1443, 1404	_	-	-
[Co(TMP)(bipy)Cl <sub>2</sub> ]	_	3412(asy) 3319(sym)	1646	1589, 1563. 1458, 1413	510	_	377
[Cu(TMP)(bipy)Cl <sub>2</sub> ].2H <sub>2</sub> O	3486 (b)	3404(asy) 3300(sym)	1649	1590, 1574, 1445, 1422	626	_	370
[Fe(TMP)(bipy)SO <sub>4</sub> ].3H <sub>2</sub> O	3550 (b)	3406(asy) 3321(sym)	1666	1591, 1560, 1508, 1420	614	474	_
[Mn(TMP)(bipy)Cl <sub>2</sub> ].2H <sub>2</sub> O	3490 (b)	3404(asy) 3320(sym)	1646	1589, 1562, 1457, 1430	514	_	381
[Ni(TMP)(bipy)Cl <sub>2</sub> ]	_	3403(asy) 3322(sym)	1651	1589, 1565, 1500, 1459	510	_	379
[Zn(TMP)(bipy)SO <sub>4</sub> ].2H <sub>2</sub> O	3480(b)	3406(asy) 3315(sym)	1639	1593, 1560, 1455, 1419	616	508	_

#### Electronic spectra and magnetic moments of the synthesised complexes

The electronic spectral absorptions of the ligands and complexes are presented in Table 3. The electronic spectrum of trimethoprim (TMP) showed two major bands the first at 47847 cm<sup>-1</sup> (209 nm) due to intra ligand  $\pi \rightarrow \pi^*$  transition of the aromatic (C=C) group. The second band at 36764 cm<sup>-1</sup> (272 nm) arose from  $n \rightarrow \pi^*$  transition due to the nitrogen atom of imine (-N=C-) group (Table 3) [67]. The co ligand (bipy) exhibited bands at 42553 cm<sup>-1</sup>(235 nm) attributed to  $\pi \rightarrow \pi^*$  transition due to C=C group and 35587 cm<sup>-1</sup> (281 nm) attributed to  $n \rightarrow \pi^*$  transition owing to the nitrogen atom of the –N=C– group [68-70]. These transitions undergo a shift in the metal complexes due to metal–ligand interaction which obviously indicated the coordination of the ligand to the metal ion [71].

The electronic spectrum of the Co(II) complex gives three bands at 14,599 cm<sup>-1</sup> (685 nm), 19,342 cm<sup>-1</sup> (517 nm) and 23,419 cm<sup>-1</sup> (427 nm). The bands observed were assigned to the transitions ,  ${}^{4}T_{1g(F)} \rightarrow {}^{4}T_{2g(F)}(v1)$ ,  ${}^{4}T_{1g(F)} \rightarrow {}^{4}A_{2g(F)}(v2)$  and  ${}^{4}T_{1g(F)} \rightarrow {}^{4}T_{1g(P)}(v3)$ , respectively, suggestive of an octahedral geometry around Co(II) ion [72-73]. The magnetic susceptibility value of 3.3 B.M was lower than the value expected for high spin three unpaired electrons (3.87 BM) and abnormally high for value of one unpaired, thus falls within the anomalous range. The observed moments of 3.3 BM can be explained by assuming an equilibrium mixture of the spin-paired (inner orbital) and spin-free (outer orbital) states in each case. Therefore, it can be 0inferred that the metal-ligand bonds must be quite strong, involving appreciable pi-bonding and that the energy difference between the two electronic states (spin-paired and spin-free) is of the order of kT [74].

The copper complex [Cu(TMP)(bipy)Cl<sub>2</sub>].2H<sub>2</sub>O exhibited two unsymmetrical absorption bands at 13369 cm<sup>-1</sup> and 23810 cm<sup>-1</sup> assigned to  ${}^{2}B_{1g} \rightarrow {}^{2}B_{2g}$  and  ${}^{2}B_{1g} \rightarrow {}^{2}E_{1g}$  transitions of a tetragonal octahedral geometry in consistent with distorted octahedral geometry [61]. A magnetic moment of 1.8 BM confirmed the monomeric nature of the copper (II) complex [75].

The Fe(II) complex had two bands at 18692 cm<sup>-1</sup> (535 nm) and 21598 cm<sup>-1</sup> (463 nm) typical of 6-coordinate, high spin and low spin octahedral geometry and were assigned to  ${}^{5}T_{2g} \rightarrow {}^{5}E_{g}$  and  ${}^{1}A_{1g} \rightarrow {}^{1}T_{2g}$  transitions and a magnetic moment of 3.10 B.M observed for this complex was indicative of spin equilibrium between the high spin and low spin octahedral geometry [76-77]. The electronic absorption spectra of manganese-complex

[Mn(TMP)(bipy)Cl<sub>2</sub>].2H<sub>2</sub>O gave two absorptions at 13123 cm<sup>-1</sup> (762 nm) and 15038 cm<sup>-1</sup> (665 nm) characteristic of low spin octahedral geometry assigned to  ${}^{2}T_{2g} \rightarrow {}^{2}A_{1g}$  and  ${}^{2}T_{2g} \rightarrow {}^{2}B_{1g}$  transitions respectively. The effective magnetic moments 2.0 of this complex was consistent of a low spin octahedral geometry [78].

The electronic spectrum of [Ni(TMP)(bipy)Cl<sub>2</sub>] exhibited two d-d transitions at 12594cm<sup>-1</sup> (794 nm) and 14368 cm<sup>-1</sup> (696 nm) assigned to  ${}^{3}A_{2g} \rightarrow {}^{3}T_{2g}$  and  ${}^{3}A_{2g} \rightarrow {}^{3}T_{1g}$  (F) respectively. Generally, square planar Ni(II) complexes are diamagnetic while octahedral and tetrahedral complexes are paramagnetic with moments in the range 2.90 – 3.40 B.M and 3.50 – 4.10 B.M respectively [79]. In this study, magnetic moment of 2.2 B.M observed for the Ni complex, showed equilibrium between the high spin octahedral and low spin octahedral geometry [80-81]. The zinc complexes [Zn(TMP)(bipy)SO<sub>4</sub>].2H<sub>2</sub>O showed only the charge transfer transitions from metal to ligand, as no d-d transition was expected due to their d<sup>10</sup> configurations. These complexes assumed a 6-coordinate octahedral geometry [82-83].

Compounds	UV bands (cm <sup>-1</sup> )	Probable transitions
Trimethoprim	47847	$\pi \rightarrow \pi^*$
(TMP)	36764	$n \rightarrow \pi^*$
2,2'-bipyridine (bipy)	42553	$\pi \rightarrow \pi^*$
	35587	$n \rightarrow \pi^*$
[Co(TMP)(bipy)Cl <sub>2</sub> ]	48309	СТ
	36232	$n \rightarrow \pi^*$
	23419	${}^{4}T_{1g(F)} \rightarrow {}^{4}T_{1g(P)}$
	19342	${}^{4}T_{1g(F)} \rightarrow {}^{4}A_{2g(F)}$
	14599	${}^{4}T_{1g(F)} \rightarrow {}^{4}T_{2g(F)}$
[Cu(TMP)(bipy)Cl <sub>2</sub> ].2H <sub>2</sub> O	48780	СТ
	35088	$n \rightarrow \pi^*$
	23810	$^{2}B_{1g} \rightarrow ^{2}E_{1g}$
	13369	${}^{2}B_{1g} \rightarrow {}^{2}B_{2g}$

Table 3: Electronic spectra data of trimethoprim, 2,2'-bipyridine and their metal complexes

[Fe(TMP)(bipy)SO <sub>4</sub> ].3H <sub>2</sub> O	48544	СТ
	36363	$\pi \rightarrow \pi^*$
	24330	$n \rightarrow \pi^*$
	21598	$^{1}A_{1g} \rightarrow ^{1}T_{2g}$
	18692	${}^{5}T_{2g} \rightarrow {}^{5}E_{g}$
[Mn(TMP)(bipy)Cl <sub>2</sub> ].2H <sub>2</sub> O	47847	СТ
	36232	$\pi \rightarrow \pi^*$
	15038	$^{2}T_{2g} \rightarrow ^{2}B_{1g}$
	13123	$^{2}T_{2g} \rightarrow ^{2}A_{1g}$
[Ni(TMP)(bipy)Cl <sub>2</sub> ]	48544	CT
	37037	$\pi \rightarrow \pi^*$
	14368	${}^{3}A_{2g} \rightarrow {}^{3}T_{1g(F)}$
	12594	$^{3}A_{2g} \rightarrow ^{3}T_{2g}$
[Zn(TMP)(bipy)SO <sub>4</sub> ].2H <sub>2</sub> O	48543	СТ
	35971	$\pi \rightarrow \pi^*$

# CT = Charge transfer



Where M = Co, Cu, Mn, Ni and n = 0, 2, Figure 3: Proposed structure of [M (TMP)(bipy)Cl<sub>2</sub>].nH<sub>2</sub>0



Where M = Zn, Fe and n = 2, 3Figure 4: Proposed structure of [M (TMP)(bipy)SO<sub>4</sub>].nH<sub>2</sub>O

#### **Antimicrobial studies**

The antimicrobial activities of the ligands, Trimethoprim, 2,2'-bipyridine and their metal complexes are presented in Table 4. The ligand 2,2'-bipyridine showed better activity against all the tested bacteria with inhibitory zone range of 22.0 to 38.0 mm in comparison with trimethoprim and the standard drug gentamycin. The greater activity exhibited by 2,2'-bipyridine might be attributed to point mutation, which caused alteration of the DNA due to the transformation of the bases in a pair of nucleotides during DNA replication, leading to oxidative damages in DNA [84].

All the metal complexes showed greater activities against gram negative *Enteropathogenic E. coli* at all concentrations compared to Trimethoprim, 2,2'-bipyridine and the reference drug gentamycin. The better activities demonstrated by all the mixed ligand complexes against *Enteropathogenic E. coli* can be explained on the basis of the Overtone's concept [85] and Tweedy'schelation theory [86], where chelation caused reduction in the polarity of the metal ion due to the partial sharing of its positive charge with the donor groups which led to increase in the delocalization of the pi-electron resulting in increased lipophilicity and so favors

permeation into the bacterial membrane to cause the death of the organisms [87-88]. The observed trend for the activities demonstrated by the mixed metal complexes was Mn > Zn > Cu> Fe > Co ~ Ni thus making [Mn(TMP)(bipy)Cl<sub>2</sub>].2H<sub>2</sub>O the most biologically active among them.

Generally, the synthesised complexes demonstrated better activities the than the standard drugs gentamycin as evidenced by their activities against *Morganella morganii* as indicated by zones of inhibition in the range 10 to 30 mm which the standard drug gentamycin has no activity. However, it was observed that the activities shown by the mixed metal complexes varies with the concentrations as the highest activities were observed at the highest concentration of 40mg/mL but as the concentration decreases the activities decreases as evidenced by the reduction in the zone of inhibitions.

In contrast, the ligands and their complexes did not exhibit antifungal activities against the tested fungus *Candida albicans* at all concentrations showing them to be potential antibacterial agents rather than as antifungal agents.

Table 4: Antimicrobial activity of ligands and its metal(II) complexes in mg/ml

Complexes	đMT			bipy			[Co(TMP)(bipy)]Cl2]		[Cu(TMP)(bipy)Cl2]. 2H2O			[Fe(TMP)(bipy)SO4]. 3H <sub>2</sub> O			[Mn(TMP)(bipy)Cl2]. 2H2O			[Ni(TMP)(bipy)Cl2]		[Zn(TMP)(bipy)SO4]. 2H <sub>2</sub> O		(+) Gentamycin			
	40	20	10	40	20	10	40	20	10	40	20	10	40	20	10	40	20	10	40	20	10	40	20	10	10
	(mg/r	nl)	(mg/n	nl)			(mg	(ml)		(mg	(mg/ml)		(mg/ml)			(mg/ml)			(mg/ml)		(mg/ml)		(µ <b>g/ml</b> )		
Candida Albicans	R≠	R≠	R≠	R≠	$\underset{\neq}{R}$	R ≠	$\underset{\neq}{R}$	$\underset{\neq}{R}$	R ≠	$\underset{\neq}{R}$	R ≠	$\underset{\neq}{R}$	$\underset{\neq}{R}$	$\underset{\neq}{R}$	$\underset{\neq}{R}$	$\underset{\neq}{R}$	$\underset{\neq}{R}$	$\underset{\neq}{R}$	$\underset{\neq}{R}$	$\underset{\neq}{R}$	$\underset{\neq}{R}$	R≠	R ≠	R≠	R≠
Enteropathogenic	32	28	20	30	28	24	38	36	30	3/	20	20	40	34	32	30	26	24	36	3/	14	36	34	30	24
L. COII								50	50	54	52	30	40	54	52	30	20	2.		7	11	20			
E. con Enterotoxigenic E.coli	22	18	16	30	28	24	18	16	14	20	17	14	20	14	13	26	25	20	20	15	12	25	18	15	30
E. con Enterotoxigenic E.coli Klebsiella pneumonia	22 28	18 26	16 22	30 34	28 32	24 28	18 15	16 10	14 R	20 20	17 18	14 16	20 25	14 20	13 14	26 30	20 25 30	20 20	20 18	15 16	12 R	25 16	18 14	15 12	30 16
E. con Enterotoxigenic E.coli Klebsiella pneumonia Leclerciaadecar Boxylata	22 28 28	18       26       22	16       22       18	30 34 30	28 32 24	24 28 22	18 15 16	16 10 14	30 14 R R	20 20 18	32 17 18 16	30 14 16 R	<ul><li>40</li><li>20</li><li>25</li><li>14</li></ul>	14       20       12	13 14 R	30 26 30 36	20 25 30 30	20 20 24	20 18 16	15 16 14	12 R 12	25 16 40	18 14 34	15 12 30	30 16 26
E. con Enterotoxigenic E.coli Klebsiella pneumonia Leclerciaadecar Boxylata Morganella morganii	22 28 28 22 22	18           26           22           16	16           22           18           14	30 34 30 38	28 32 24 32	24 28 22 30	18 15 16 19	16           10           14           14	14 R R 12	20 20 18 25	32       17       18       16       20	14 16 R 12	<ul><li>40</li><li>20</li><li>25</li><li>14</li><li>22</li></ul>	14       20       12       20	13 14 R 12	30       26       30       36       30	20 25 30 30 25	20 20 24 20	20 18 16 20	15       16       14       10	12 R 12 10	25 16 40 20	18       14       34       18	15 12 30 15	30 16 26 R
E. con Enterotoxigenic E.coli Klebsiella pneumonia Leclerciaadecar Boxylata Morganella morganii Salmonella typhi	22       28       28       22       20	18       26       22       16       18	16         22         18         14         16	30         34         30         38         36	28 32 24 32 30	24 28 22 30 26	18 15 16 19 20	16       10       14       14       18	30       14       R       12       12	20 20 18 25 20	32       17       18       16       20       16	14 16 R 12 12	<ul> <li>40</li> <li>20</li> <li>25</li> <li>14</li> <li>22</li> <li>24</li> </ul>	14       20       12       20       20	13 14 R 12 18	30         26         30         36         30         26	20 25 30 30 25 24	20 20 24 20 20 20	20 18 16 20 18	15       16       14       10       16	12 R 12 10 14	25 16 40 20 20	18 14 34 18 18	15 12 30 15 14	30 16 26 R 16

TMP = Trimethoprim, bipy = 2,2' bipyridine, R = Resistance,  $R^{\neq}$  = No growth, (+) = positive control

http://www.unn.edu.ng/nigerian-research-journal-of-chemical-sciences/

#### CONCLUSION

Mixed-ligands complexes of trimethoprim (TMP) and 2,2'-bipyridine (bipy) with Co(II), Cu(II), Fe(II), Mn(II), Ni(II) and Zn(II) were synthesised and characterised spectroscopically. From the infrared spectra data, TMP behaves as a bidentate ligand bonding to the metals via the N atom of the pyrimidine amino group and nitrogen atom of the azomethine moiety while the bipy coordinated through the diimine nitrogen atoms. The electronic spectra data showed that all the metal(II) complexes were monomeric and octahedral. From the antimicrobial studies, the complexes and their ligands did not show antifungal activity, however, the observed trend for the antibiacterial activities demonstrated by the mixed metal complexes was Mn >Zn > Cu > Fe > Co ~ Ni thus making [Mn(TMP)(bipy)Cl<sub>2</sub>].2H<sub>2</sub>O the most biologically active among them. It was also observed that antibacterial activities exhibited varied directly with concentration as the highest activities were observed at the highest concentration of 40mg/mL.

#### Acknowledgement

The authors thank Bond Chemical Plc Awe, Oyo State, Nigeria and Unique Pharmaceutical Lagos State, Nigeria for the gift of Trimethoprim. Mr. Sunday of Pharmaceutical Microbiology Department, University of Ibadan, Oyo State, Nigeria, is also appreciated for his technical assistance.

## REFERENCES

- Cooke, B. M., Mohandas, N. & Copel, R. L. (2004). Malaria and the red blood cell membrane, Semin Hematol., 41(2), 173–188.
- [2] Demain, A.L. (2009). Antibiotics: Natural products essential to human health, *Medicinal Research Reviews*, 29 (6), 821-842.
- [3] Verhoef, J. & Fluit, A. (2006). Surveillance uncovers the smoking gun for resistance emergence, *Biochem. Pharmacol.*, 71 (7), 1036–1041.
- [4] Leeb, M. (2004). A Shot in the arm, Nature. 431, 892-893.
- [5] Ajibade, P. A & Zulu, N. H. (2010). Synthesis, characterization, and antibacterial activity of metal complexes of phenylthiourea: the X-ray single crystal structure of [Zn(SC(NH<sub>2</sub>)NHC<sub>6</sub>H<sub>5</sub>)<sub>2</sub>(OOCCH<sub>3</sub>)<sub>2</sub>] · C<sub>2</sub>H<sub>5</sub>OH, *J. Coord. Chem.*, 63 (18), 3229–3239.
- [6] Loginova, N.V., Koval'chuk, T.V., Zheldakova, R. A., Osipovich, N. P., Sorokin, V. L., Polozov, G. I., Ksendzova, G. A., Glushonok, G. K., Chernyavskaya, A.A. & Shadyro, O. I. (2006).

Synthesis and biological evaluation of copper (II) complexes of sterically hindered *o*-aminophenol derivatives as antimicrobial agents, *Bioorg. Med. Chem. Lett.*, 16 (20), 5403–5407.

- [7] World Health Organization, The World Health Report (2004)-Changing History, Annex Table 2: Deaths By Cause, Sex and Mortality Stratumin WHO Regions, Estimates For 2002, WHO, Washington, DC, USA,
- [8] Namba, K., Zheng, X., Motoshima, K., Kobayashi, H., Tai, A., Takahashi, E., Sasaki, K., Okamoto, K. & Kakuta, H. (2008). Design and synthesis of benzenesulfonanilides active against methicillin resistant *Staphylococcus aureus* and vancomycin-resistant *Enterococcus, Bioorg.Med. Chem.*, 16 (11), 6131–6144.
- [9] Rajapakse, C. S. K., Martínez, A., Naoulou, B., Jarzecki, A. A., Suárez, L., Deregnaucourt, C., Sinou, V., Schrével, J., Musi, E., Ambrosini, G., Schwartz, G. K. & Sánchez-Delgado, R. A. (2009). Synthesis, Characterization, and in vitro Antimalarial and Antitumor Activity of New Ruthenium(II) Complexes of Chloroquine, *Inorg. Chem.*, 48 (3), 1122–1131.
- [10] Ang, W.H., Daldini, E., Scolaro, C., Scopelliti, R., Juillerat-Jeannerat, L. & Dyson, P. J. (2006). Development of Organometallic Ruthenium–Arene Anticancer Drugs That Resist Hydrolysis, *Inorg. Chem.*, 45 (22), 9006–9013.
- [11] Allardyce, C. S., Dorcier, A., Scolaro, C. & Dyson, P. J. (2005). Development of organometallic (organo-transition metal) pharmaceuticals, *Appl. Organomet.Chem.*, 19 (1), 1-10.
- [12] Refat, M. S. & El-Shazly, S. A. (2010). Identification of a new anti-diabetic agent by combining VOSO<sub>4</sub> and vitamin E in a single molecule: Studies on its spectral, thermal and pharmacological properties, *Eur. J. Med. Chem.*, 45 (7), 3070–3079.
- [13] Hussein, B. H. M., Azab, H. A., El-Azab, M. F. & El-Falouji, A. I. (2012). A novel antitumor agent, Ln(III) 2-thioacetate benzothiazole induces anti-angiogenic effect and cell death in cancer cell lines, *Eur. J. Med. Chem.*, 51, 99–109.
- [14] Thompson, K. H., Chiles, J., Yuen, V. G., Tse, J., McNeill, J. H. & Orvig, C. (2004). Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes, *J. Inorg.Biochem.*, 98 (5), 683–690.

- [15] Desoize, B. (2004). Metals and Metal Compounds in Cancer Treatment, *Anticancer Research*, 24 (3A), 1529-1544.
- [16] Sekhon, B. S. & Gandhi, L. (2006). Medicinal uses of inorganic compounds -1, *Resonance*, 11 (4), 75–89.
- [17] Wang, D & Lippard, S.J. (2005). Cellular processing of platinum anticancer drugs, *Nat.Rev. Drug Discov.*, 4, 307-320.
- [18] delas Cuevas, C., Sanz, E & de la Fuente, J. (2003). Benzodiazepines: more "behavioural" addiction than dependence, *Psychopharmacology*, 167, 297-303.
- [19] McEvoy, G.K. (ed.). (2002) American hospital formulary service-drug information. Bethesda, MD: American Society of Health-System Pharmacists, Inc. (Plus Supplements), 843.
- [20] Masters, P.A., O'Bryan, T. A., Zurlo, J., Miller, D. Q. & Joshi, N. (2003). Trimethoprim-Sulfamethoxazole Revisited, Arch.Intern. Med., 163, 403-410
- [21] Lawal, A., Ayanwale, P. A., Obaleye, J. A., Rajee, A. O. Babamale, H.F. & Lawal, M. (2017). Synthesis, Characterization and Biological Studies of Mixed Ligands Nicotinamide-Trimethoprim Complexes, *IJCMER*, 4 (1), 97-101.
- [22] Drews, J. (2000). Drug Discovery: A Historical Perspective, *Science*, 287 (5460), 1960-1964.
- [23] Caron, F., Wehrle, V & Etienne, M. (2017). The comeback of trimethoprim in France Trimethoprim: an antibiotic undergoing réhabilitation in France, *Médecineet Maladies Infectieuses*, 47(4), 253-260.
- [24] Yao, J. & Moellering, R. (2011). Antibacterial Agents, *In Versalovic J, Carroll K, Funke G, Jorgensen, J., Landry, M, Warnock, D. (ed)*, *Manual of Clinical Microbiology, 10th Edition*, ASM Press, Washington, DC, 1043-1081
- [25] Doud, M.S., Light, M., Gonzalez, G., Narasimhan, G. & Mathee, K. (2010). Combinatio of 16S rRNA variable regions provides a detailed analysis of bacterial community dynamics in the lungs of cystic fibrosis patients, *Hum Genomics*, 4(3), 147-169.
- [26] Kim, H.Y., Kim, T-H & Yu, S. (2015). Photolytic degradation of sulfamethoxazole and trimethoprim using UV-A, UV-C and vacuum-UV (VUV), *J. Environ. Sci. Heal. A.*, 50(3), 292-300
- [27] Lawn, S. D., Butera, S.T. & Folks, T. M. (2001). Contribution of Immune Activation to the

Pathogenesis and Transmission of Human Immunodeficiency Virus Type 1 Infection, Clin. Microbiol. Rev., 14(4), 753-777.

- [28] Rungoe, C., Malchau, E.L., Larsen, L.N. & Shroeder, H. (2010). Infections during induction therapy for children with acute lymphoblastic leukemia. The role of sulfamethoxazole–trimethoprim (SMX–TMP) prophylaxis, *Pediatr. Blood Cancer*, 55(2), 304-308.
- [29] Bhadra, D., Bhadra, S. & Jain, N.K. (2005). PEGylated peptide-based dendriticnanoparticulate systems for delivery of artemether, J. Drug DelivSci Technol., 15(1), 65-73.
- [30] Eliopoulus, G.M. & Huovinen, P. (2001). Resistance to trimethoprim-sulfamethoxazole, *Clin. Infect.Dis.*, 32 (11) 1608–1614.
- [31] Bonacorso, H.G., Andrighetto, R., Frizzo, C. P., Zanatta, N. & Martins, M. A. P. (2015). Recent advances in the chemistry of 1,10-Phenanthrolines and their metal complex derivatives: synthesis and promising applications in medicine, technology, and catalysis. DOI: http://dx.medra.org/10.17374/targets.2016.19.1
- [32] Al-Noor, T. H., Ibrahim, I.A. J. & Jawad, M. M. (2015). Studies on the interaction and effect of Mn(II), Fe(II), Co(II), Ni(II), Cu(II), Zn(II) and Cd(II) mixed- ligand complexes of cephalexin mono hydrate and furan-2-carboxylic acid to different DNA sources, *JOCPR*, 7(4), 815-823.
- [33] Bao, F., Lu, X., Kang, B. & Wu, Q. (2006). Vinyl polymerization of norbornene catalyzed by a series of bis (β-ketoiminato) nickel (II) complexes in the presence of methylaluminoxane, *Eur. Polym. J.*, 42 (2), 928-934.
- [34] Sathiyaraj, S., Sampath, K., Butcher, R. J., Pallepogu, R. & Jayabalakrishnan, C. (2013). Designing, structural elucidation, comparison of DNA binding, cleavage, radical scavenging activity and anticancer activity of copper(I) complex with 5-dimethyl-2-phenyl-4-[(pyridin-2-ylmethylene)amino]-1,2-dihydro-pyrazol-3-one Schiff base ligand, *Eur. J.Med.Chem.*, 64, 81-89.
- [35] Swavey, S. & Brewer, K. J. (2004). Comprehensive Coordination Chemistry II.Pergamon Press, Oxford 135.
- [36] Klingele, J., Dechert, S. & Meyer, F. (2009). Polynuclear transition metal complexes of metalmetal-bridging compartmental pyrazolate ligands, *Coord. Chem. Rev.* 253(21-22), 2698-2741.

- [37] Selvaganapathy, M. & Raman, N. (2016). Pharmacological Activity of a Few Transition Metal Complexes: A Short Review, J. Chem. Biol. Ther. 1 (2), 1-17.
- [38] Kaes, C., Katz, A. & Hosseini, M.W. (2000). Bipyridine: the most widely used ligand. A review of molecules comprising at least two 2, 2 '-bipyridine units, *Chem. Rev.* 100 (10), 3553-3590.
- [39] Hapke, M., Brandt, L. &Lutzen, A. (2008). Versatile tools in the construction of substituted 2, 2'bipyridines—cross-coupling reactions with tin, zinc and boron compounds, *Chem. Soc. Rev.*, 37, 2782-2797.
- [40] Fu, P., Wang, S., Hong, K., Li, X., Liu, P., Wang, Y. & Zhu, W. (2011). CytotoxicBipyridines from the Marine-Derived Actinomycete Actinoalloteichuscyanogriseus WH1-2216-6, J. Nat. Prod., 74(8), 1751–1756.
- [41] Lu, J-Y. & Ardnt, H-D. (2007). Hetero Diels–Alder Synthesis of 3-Hydroxypyridines: Access to the Nosiheptide Core, J. Org. Chem., 2007, 72, 11, 4205–4212.
- [42] Fu, P., Liu, P., Li, X., Wang, Y., Wang, S., Hong, K. & Zhu, W.(2011). Cyclic Bipyridine Glycosides from the Marine-Derived Actinomycete Actinoalloteichus cyanogriseus WH1-2216-6, Org. Lett., 13 (22), 5948-5951.
- [43] Waldman, A.J., Ng, T.L., Wang, P. & Balskus, E.P. (2017). Heteroatom–Heteroatom Bond Formation in Natural Product Biosynthesis, *Chem. Rev.*, 117 (8), 5784–5863
- [44] Liu, J-K. (2005). N-Containing Compounds of Macromycetes, Chem. Rev., 105(7), 2723-2744.
- [45] Pommier, Y., Leo, E., Zhang, H.L. & Marchand, C. (2010). DNA Topoisomerases and their Poisoning by anticancer and antibacterial drugs, *Chem. Biol.*, 17 (5), 421-433.
- [46] Wellington, K.W. (2015). Understanding cancer and the anticancer activities of naphthoquinones a review, *RSC Adv.*,5, 20309-20338
- [47] Doyle, A., Felcman, J., do Prado Gombradella, M.T., Verani, C.N. & Tristao, M.L.B. (2000). Anhydrous copper(II) hexanoate from cuprous and cupric oxides. The crystal and molecular structure of Cu<sub>2</sub>(O<sub>2</sub>CC<sub>5</sub>H<sub>11</sub>)<sub>4</sub>, *Polyhedron*, 19(26–27), 2621-2627.
- [48] İspir, E., Kurtoğlu, M., Purtaş, F. & Serin, S. (2005). Synthesis and Antimicrobial Activity of New Schiff Bases Having the –SiOR Group (*R* = CH 3 or CH<sub>2</sub>CH<sub>3</sub>), and their Transition Metal Complexes, *Transition Met Chem.*, 30, 1042–1047
- [49] Warad, D.U., Satish, C.D., Kulkarni, V.H. & Bajgur, C.S. (2000). Synthesis, structure and reactivity of zirconium(IV), vanadium(IV), cobalt(II), nickel(II) and copper(II) complexes derived

from carbohydrazide schiff base ligands, IJCA, 39A, 415-420.

- [50] Maurya, R. C., Patel, P. & Rajput, S.(2003). Synthesis and characterization of Mixed-Ligand Complexes of Cu(II), Ni(II), Co(II), Zn(II), Sm(III), and U(VI)O<sub>2</sub>, with a Schiff Base Derived from the Sulfa Drug Sulfamerazine and 2,2'-Bipyridine,*Synth. React. Inorg.Met..Org. Chem.*, 33 (5),801– 816.
- [51] Chandraleka, S., Ramya, K., Chandramohan, G., Dhanasekaran, D., Priyadharshini, A. & Panneerselvam, A. (2014). Antimicrobial mechanism of copper (II) 1, 10-phenanthroline and 2, 2'bipyridyl complex on bacterial and fungal pathogens, *J. Saudi Chem. Soc.*, 18 (6), 953-962.
- [52] Alaghaz, A.M.A., Farag, R.S., Elnawawy, M. A. &Ekawy, A.D.A. (2016). Synthesis and spectral characterization studies of new trimethoprim-diphenylphosphate metal complexes, *IJSR*, 5 (1), 1220-1229.
- [53] Osowole, A. A., Wakil, S. M. & Alao, O. K. (2015). Synthesis, characterization and antimicrobial activity of some mixed Trimethoprim-Sulfamethoxazole metal drug complexes, *World Appl. Sci. J.*, 33 (2), 336-342.
- [54] Eugene-Osoikhia, T.T., Badmus, T.O. & Ayeni, F. (2020). Synthesis, Characterisation and antimicrobial studies of Metal(II) Complexes of Ofloxacin and Metronidazole, *ChemSearch*, 11(1), 74-82.
- [55] Eugene-Osoikhia, T.T., Obodozie, J.C. & Ayeni, F. (2020). Synthesis, characterization and antimicrobial studies of Fe (II) and Cu(II) complexes of acetylated and benzoylated derivatives of ciprofloxacin, *NJCR*, 25(1), 25-43.
- [56] Shahzadi, S., Ali, S., Bhatti, M.H., Fettouhi, M. & Athar, M. (2006) Chloro-diorganotin(IV) complexes of 4-methyl-1-piperidine carbodithioic acid: Synthesis, X-ray crystal structures, spectral properties and antimicrobial studies, *J. Organomet. Chem.*, 691 (8), 1797-1802.
- [57] Golcu, A., Tumer, M., Demirelli, H. & Wheatley, R.A. (2005). Cd (II) and Cu (II) complexes of polydentate Schiff base ligands: synthesis, characterization, properties and biological activity, *Inorganica Chim. Acta*, 358 (6),1785-1797.
- [58] Castillo-Blum, S. E. & Barba-Behrens, N. (2000). Coordination chemistry of some biologically active ligands, Coord. *Chem. Rev.* 196, 3–30.
- [59] Beyramabadi, S.A., Eshtagh-Hosseini, H., Housaindokht, M.R. & Morsali, A. (2011). Synthesis, experimental and theoretical characterization of Cu(II) complex of 2-chloropyrimidine, *Sci. Res.*

Essays. 6 (20), 4341-4346.

- [60] Gulcan, M., Sonmez, M. & Berber, I. (2012). Synthesis, characterization, and antimicrobial activity of a new pyrimidine Schiff base and its Cu (II), Ni (II), Co (II), Pt (II), and Pd (II) complexes, *Turk. J. Chem.* 36, 189-200.
- [61] Ahmed, E.M., Marzouk, N.A., Hessien, S.A. & Ali, A.M. (2011). Synthesis, reactions and antimicrobial activity of some new thienopyridine and thienopyrimidine derivatives, *WJC*, 6 (1), 25-31.
- [62] Abu-Hussen, A.A.A. (2006). Synthesis and spectroscopic studies on ternary bis-Schiff-base complexes having oxygen and/or nitrogen donors, J. Coord. Chem., 59 (2), 157-176.
- [63] Anupama, B. & Kumari, C.G. (2013). Cobalt (II) complexes of ONO donor Schiff bases and N, N donor ligands: synthesis, characterization, antimicrobial and DNA binding study, *IJRCE*, 3 (2), 172-180
- [64] Soliman, A.A. & Mohamed, G.G. (2004). Study of the ternary complexes of copper with salicylidene-2-aminothiophenol and some amino acids in the solid state, *Thermochim. Acta.*,421 (1), 151-159.
- [65] Mukherjee, R. (2000). Coordination chemistry with pyrazole-based chelating ligands: molecular structural aspects, *Coord. Chem. Rev.*, 203 (1), 151-218.
- [66] Eugene-Osoikhia, T. T., Akinpelu, I. O. & Odiaka, T. I. (2019). Synthesis, Characterization and Antimicrobial Studies of Transition Metal Complexes of Schiff Base derived from Salicylaldehyde and L-Tyrosine Amino Acid, NJCR, 24(1), 46-56.
- [67] Figgis, B. N. & Hitchman, M.A. (2000). Ligand field theory and its Application. Wiley-VCH, New York, Singapore, Toronto.
- [68] Imam, H., Kumar, B. & Shafayat, M. (2011). Mixed Ligand Complexes of Transition Metal Chelates of 1-nitroso-2-naphthol and 8-hydroxyquinoline with Picolinic Acid and Quinaldinic acid *Orient. J. Chem.*, 27 (1), 287-291.
- [69] Scarborough, C.C. & Wieghardt, K. (2011). Electronic structure of 2, 2'-bipyridine organotransition-metal complexes. Establishing the ligand oxidation level by density functional theoretical calculations, *Inorg. Chem.*, 50 (20), 9773-9793.

- [70] Wojciechowska, A., Staszak, Z., Bronowska, W., Pietraszko, A. & Cieslak-Golonka, M. (2001).
  Spectroscopic and structural studies of chromate ions in zinc complexes with 2, 2'-bipyridine.
  Analysis of the lowest triplet states in the CrO42– entity, *Polyhedron*, 20 (15-16) (2001) 2063-2072.
- [71] Madhupriya, S. & Elango, K. P. (2014). Synthesis, spectral characterization and catalytic activity of Co (II) complexes of drugs: Crystal structure of Co (II)–trimethoprim complex, *Spectrochim.Acta A Mol. BiomolSpectrosc.*, 118, 337-342.
- [72] Omar, M.M. & Mohamed, G.G. (2005). Potentiometric, spectroscopic and thermal studies on the metal chelates of 1-(2-thiazolylazo)-2-naphthalenol, *Spectrochim.Acta A Mol. BiomolSpectrosc.*, 61(5), 929-936.
- [73] Winston, S., Stylianides, N., Tulloch, A.A.D., Wright, J.A. & Danopoulos, A.A. (2004). Picoline and pyridine functionalized chelate N-heterocyclic carbene complexes of nickel: synthesis and structural studies, *Polyhedron*, 23(17), 2813-2820.
- [74] Gibson, V.C., Redshaw, C. & Solan, G. A. (2007). Bis(imino)pyridines: Surprisingly Reactive Ligands and a Gateway to New Families of Catalysts, *Chem. Rev.*, 107(5), 1745–1776
- [75] Ajibade, P.A. & Kolawole, G. (2008). Synthesis, characterization and antiprotozoal studies of some metal complexes of antimalarial drugs, *Transit. Met. Chem.*, 33 (4), 493–497.
- [76] Kitchen, J.A., Olguin, J., Kulmaczewski, J. R., White, N.G., Milway, V.A., Jameson, G.N.L., Tallon, J.L. & Brooker, S. (2013). Effect of N<sup>4</sup>-Substituent Choice on Spin Crossover in DinuclearIron(II) Complexes of Bis-Terdentate 1,2,4-Triazole-Based Ligands, *Inorg. Chem.*, 52 (19), 11185-11199.
- [77] Rudavskyi, A., Havenith, R.W.A., Broer, R., de Graaf, C. & Sousa, C. (2013). Explanation of the site-specific spin crossover in Fe(mtz)<sub>6</sub>(BF<sub>4</sub>)<sub>2</sub>, *Dalton Trans.*, 42, 14702-14709.
- [78] Sahar, A. P. Majumdar, S. Goswami, (2000). Low-spin manganese(II) and cobalt(III) complexes of *N*-aryl-2 pyridylazo phenyl amines: new tridentate N,N,N-donors derived from cobalt mediated aromatic ring amination of 2-(phenylazo) pyridine. Crystal structure of a manganese(II) complex, *J. Chem. Soc. Dalton Trans.*, 11, 1703-1708.

- [79] Masoud, M.S., Amira, M.F., Ramadan, A.M. & El-Ashry, G.M. (2008). Synthesis and characterization of some pyrimidine, purine, amino acid and mixed ligand complexes, *Spectrochim Acta A. Mol Biomol.Spectrosc.*, 69 (1), 230-238.
- [80] Ohtsu, H. & Tanaka, K. (2004). Equilibrium of low-and high-spin states of Ni (II) complexes controlled by the donor ability of the bidentate ligands, *Inorg Chem.*, 43 (9), 3024-3030.
- [81] Ohtsu, H. & Tanaka, K. (2005). Electronic Structural Changes between Nickel(II)–Semiquinonato and Nickel(III)–Catecholato States Driven by Chemical and Physical Perturbation, *Chem. Eur. J.*, 11, 3420-3426.
- [82] Raman, N., Kulandaisamy, A. & Jeyasubramanian, K. (2001). Synthesis, spectroscopic characterization, redox, and biological screening studies of some schiff base transition Metal(II) complexes derived from salicylidene-4-aminoantipyrine and 2-amino phenol/ 2aminothiopheno Synth. React. Inorg.Met. .Org. Chem., 31 (7), 1249-1270.
- [83] Onal, Z., Zengin, H. & Sonmez, M. (2011). Synthesis, characterization, and photoluminescence properties of Cu (II), Co (II), Ni (II), and Zn (II) complexes of N-aminopyrimidine-2-thione, *Turk. J. Chem.* 35, 905-914.
- [84] Gazi, I., Bahrim, G.E., Dinica, R. & Demeunynck, M. (2008). In vitro antimicrobial activity evaluation of new nitrogen heterocycles derivates from acridine, *Rom. Biotechnol.Lett.*, 13 (5), 87-92.
- [85] Joseyphus, R.S. & Nair, M.S. (2008). Antibacterial and antifungal studies on some schiff base complexes of zinc (II), *Mycobiology*. 36 (2), 93-98.
- [86] Raman, N., Raja, S. J. & Sakthivel, A. (2009). Transition metal complexes with Schiff-base ligands: 4-aminoantipyrine based derivatives-a review, J. Coord. Chem., 62 (5), 691-709.
- [87] Mahmoud, W. H., Mohamed, G. G. & El-Dessouky, M. M. I. (2014). Synthesis, characterization and in vitro biological activity of mixed transition metal complexes of lornoxicam with 1, 10phenanthroline, *Int. J. Electrochem. Sci.* 9 (2014) 1415–1438.
- [88] Eugene-Osoikhia, T.T., Aleem, A. O. & Ayeni, F. (2020). Synthesis, characterisation and antimicrobial studies of mixed ligands Metal (II) complexes of sulfamethoxazole and N,N- Donors heterocycles, *FUDMA Journal of Sciences (FJS)*, 4 (2),217-232.